Suspended

Exercise Capacity and Quality of Life in Patients With Idiopathic Pulmonary Hypertension and Eisenmenger Syndrome Receiving Short Term Oral L-Citrulline Malate

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

L-Citrulline Malate

Drug
Who is being recruted

Congenital Abnormalities+8

+ Cardiovascular Diseases

+ Heart Defects, Congenital

From 15 to 70 Years
+14 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Early Phase 1
Interventional
Study Start: August 2012
See protocol details

Summary

Principal SponsorMasih Daneshvari Hospital
Study Contactbabak sharif kashani, CardiologistMore contacts
Last updated: August 12, 2013
Sourced from a government-validated database.Claim as a partner

Study start date: August 1, 2012

Actual date on which the first participant was enrolled.

Pulmonary vascular tone is maintained by the action of vasoprotective compounds including nitric oxide (NO)(1).NO can be synthesized endogenously in the body via L-arginine and NOS-independent mechanism from the anion nitrite (NO2-)(2,3).Nitric oxide (NO) causes cyclic guanosine monophosphate-mediated vasodilatation of the pulmonary vasculature. Endogenous NO is also produced from the metabolism of citrulline; an amino acid generated by the urea cycle (4). NO is critical for normal development of the pulmonary vasculature and loss of this vasodilator factor and subsequent endothelial dysfunction is proposed as one of the possible explanations for development of pulmonary hypertension (1). From a clinical standpoint, pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD).Its presence is associated with shorter survival and worse clinical outcome. In a setting of COPD, pulmonary hypertension tends to be of moderate severity and progresses slowly. Recent investigations have demonstrated endothelial dysfunction and changes in the expression of endothelial-derived mediators that regulate vascular tone and cell growth in the pulmonary arteries of patients with mild disease(5). Pulmonary vascular involvement from congenital heart disease like Eisenmeger syndrome is another important category of patients with PAH. In this congenital disease pulmonary vascular involvement follows a period in which pulmonary resistance is low and pulmonary blood flow is high (6, 7, 8). Finally, Idiopathic pulmonary hypertension (IPAH) is the third category of these patients. IPAH has unknown etiology and is characterized by progressive obliteration of small and medium size pulmonary arteries; elevation in pulmonary arterial pressure, and an increase in pulmonary vascular resistance. Presence of these pathologies eventually leads to right heart failure and death (9).

Principal SponsorMasih Daneshvari Hospital
Study Contactbabak sharif kashani, CardiologistMore contacts
Last updated: August 12, 2013
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

25 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 15 to 70 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Congenital AbnormalitiesCardiovascular DiseasesHeart Defects, CongenitalHeart DiseasesHypertension, PulmonaryLung DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesRespiratory Tract DiseasesCardiovascular AbnormalitiesEisenmenger ComplexFamilial Primary Pulmonary Hypertension

Criteria

3 inclusion criteria required to participate
a mean pulmonary arterial pressure (PAP) >= 25 mmHg at rest as assessed by right heart catheterization(RHC) (11,12)

all patients less than 70 years old

patients with a six-minute walking distance of more than 100 meters (m)

11 exclusion criteria prevent from participating
all patients more than 70 years old

carrier of known neoplasias

detected immunosuppressive illnesses

drug or alcohol abuse, and

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
L-Citrulline malate, 1gr, oral, divided 3 times a day,for 2 weeks

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

MasihDH

Tehran, IranOpen MasihDH in Google Maps
SuspendedOne Study Center